Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Sumitomo Dainippon Pharma reports results for quarter ended 30 June 2026

For the quarter ending 30 June 2026, 1 analyst expects earnings per share of 19.13 JPY, a decline of 32.19% year on year. On average, 3 analysts forecast revenue of 113.31 billion JPY for the quarter, an increase of 4.91% versus the prior year. For the current fiscal year, 7 analysts estimate average earnings per share of 196.71 JPY and revenue of 548.56 billion JPY. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2023, Sumitomo Dainippon Pharma has already paid €0.0444 in dividends. The last payout was in June 2023.

Financials

In the last quarter, Sumitomo Dainippon Pharma had revenue of €697.63M and net profit of €91.57M

(EUR)	June 2026	YoY
Revenue	697.63M	9.49%
Gross profit	366.77M	2.69%
Net profit	91.57M	38.51%
EBITDA	120.21M	22.20%

Fundamentals

Metric	Value
Market capitalization	€4.68B
Number of shares	448.59M
52-week high/low	€18.66 - €6.74
Dividends	No
Beta	0.47
P/E ratio	6.57
PEG ratio	0.01
P/B ratio	1.96
P/S ratio	1.74

Company profile

Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastrointestinal; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. It also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.